Articles On Biotron (ASX:BIT)

Title Source Codes Date
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead BIT 15 hours ago
November Winners: ASX investors were spooked by Omicron, but wooed by Julimar, hydrogen and the metaverse

For the second month in a row the ASX was hit by a major sell-off in the last few days of the month and it took the bourse from what was then a 0.5% gain to a 1.56% loss in November. Just when we thought we were out of the worst of COVID, w...

Stockhead BIT 6 days ago
Closing Bell: ASX makes up lost ground, still finishes 0.54% down

ASX recovered some lost ground in arvo trade but still finished 0.54% down, as markets continue to be shaken by the discovery of the omicron variant of COVID-19 and falling oil prices. Resources and tech managed to finish in the green – by...

Stockhead BIT 1 week ago
10 at 10: Investors in these ASX stocks can see light at the end of the tunnel this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead BIT 1 week ago
ScoPo’s Powerplays: Christmas rally runs out of puff, but market awaits crucial release from Neuren

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Stockhead BIT 1 week ago
Market Highlights and 5 ASX Small Caps to watch on Friday

Wall Street closed for Thanksgiving No major leads from global markets overnight, as Wall Street was closed for Thanksgiving. Elsewhere, new data showed COVID infections in Europe continue to surge higher. With winter approaching, the conti...

Stockhead BIT 1 week ago
Biotron Drug Effective Against COVID-19 In Animals

BIT225 administered orally significantly reduced viral load in the lungs and blood of animals challenged with SARS-CoV-2. BIT225 protected against severe disease, indicated by the significant prevention of body weight loss in animals trea...

FNArena BIT 1 week ago
Closing Bell: One biotech more than doubles, another drops 30pc on debut

The ASX closed just 0.11% higher today but there were no shortage of small cap winners, led by Antiviral biotechnology stock Biotron (ASX:BIT). It announced that its lead drug candidate — BIT225 — had been shown to be effective against COVI...

Stockhead BIT 2 weeks ago
ASX Health Stocks: Biotron gets a boost with promising in vivo study for COVID-19 treatment

Antiviral biotechnology stock Biotron (ASX:BIT) turned heads on the ASX this morning, after announcing that its lead drug candidate — BIT225 — had been shown to be effective against COVID-19 in animals. After tracking from ~8c to below 5c t...

Stockhead BIT 2 weeks ago
Biotron’s (ASX:BIT) drug effective against COVID-19 in animals

Biotron’s (BIT) lead drug, BIT225, has been effective against COVID-19 in animals The drug was given orally and significantly reduced viral load in the lungs and blood Additionally, the company also tested BIT225 in an in-vitro study in c...

themarketherald.com.au BIT 2 weeks ago
The Biotron (ASX:BIT) share price just exploded 86% on COVID drug update

The Biotron Limited (ASX: BIT) share price is rocketing upwards today after the company announced its lead clinical asset successfully treated COVID-19 symptoms in mice as part of a study. In the study, the drug, BIT225, was found to reduc...

Motley Fool BIT 2 weeks ago
Biotron's BIT225 effective against COVID-19 in animal study

Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research...

BiotechDispatch BIT 2 weeks ago
10 at 10: These ASX stocks are the most imposing this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead BIT 2 weeks ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead BIT 2 weeks ago
Biotron commences two new clinical trials of BIT225

Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations.

BiotechDispatch BIT 1 month ago
Biotron commences two new clinical trials of BIT225

Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations.

BiotechDispatch BIT 1 month ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead BIT 3 months ago
Dr Boreham’s Crucible: With five trials and $100m, cancer-hunter Clarity’s future is clear

In the spirit of the recently-concluded Olympics and ongoing Paralympics, congratulations to the backers of the radiopharmaceuticals group for a record-breaking performance after listing this week. In raising $92 million, Clarity (ASX:CU6)...

Stockhead BIT 3 months ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead BIT 3 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead BIT 4 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead BIT 4 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead BIT 5 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead BIT 5 months ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead BIT 8 months ago
AstraZeneca’s COVID-19 fight hits the skids; ASX small cap Biotron says ‘We’re on track’

It’s easy to just think of Pfizer and AstraZeneca as the only two companies fighting COVID-19 in Australia. But Biotron ... Read More The post AstraZeneca’s COVID-19 fight hits the skids; ASX small cap Biotron says ‘We’re on track’ appeared...

Stockhead BIT 8 months ago
Why did ASX-listed Shares Unibail-Rodamco-Westfield, FlexiGroup and Biotron end in the red zone?

Summary ASX 200 listed retail company Unibail-Rodamco-Westfield disclosed a €9.0 billion RESET plan for strengthening its balance sheet and improving financial flexibility. Financial service provider FlexiGroup had completed Retail Enti...

Kalkine Media BIT 1 year ago
Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021... The...

MoneyMorning BIT 1 year ago
Why Biotron, Fortescue, Ramelius, & Temple & Webster are storming higher

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to snap its losing streak with a solid gain. At the time of writing the benchmark index is up 0.4% to 5,949.2 points. Four shares that are climbing more than most today a...

Motley Fool BIT 1 year ago
Biotron ruffles through its compound database in search of COVID-19 drug

The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-2, the coronavirus that causes the COVID...

SmallCaps BIT 1 year ago
Pharmaxis dealt another blow as partner backs out of second drug development

Pharmaxis (ASX:PXS) and Biotron (ASX:BIT) have gone in polar opposite directions in 2020 and today the gap widened further. Biotron has now nearly doubled in 2020 while Pharmaxis has nearly halved. Pharmaxis ended 2019 with a big blow which...

Stockhead BIT 1 year ago
Biotron share price rockets 47% higher on COVID-19 compound testing update

The Biotron Limited (ASX: BIT) share price has rocketed higher on Monday after the release of an update. In early trade the clinical stage biotechnology company’s shares were up as much as 47% to 14 cents. They have since given back much o...

Motley Fool BIT 1 year ago
10 at 10: These ASX stocks are leading the rally this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead BIT 1 year ago
Scopo’s health powerplays: The cash caboose keeps rolling on

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

Stockhead BIT 1 year ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

Stockhead BIT 1 year ago
Biotron share price rockets 30% on latest antiviral drug data

The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the effectiveness of its lead antiviral drug BIT225, used for fighting HIV-1 infections. The Biotron share price is...

Motley Fool BIT 1 year ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

Stockhead BIT 1 year ago
Biotron’s BIT225 drug show to enhance body’s immune response to HIV

Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect. The company is presenting new data on BIT225’s positive...

SmallCaps BIT 1 year ago
Biotron to present the latest data on BIT225

Biotron (ASX:BIT) has announced it will present the latest data on BIT225 HIV-1 at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July.

BiotechDispatch BIT 1 year ago
Health: Biotron’s anti-HIV therapy could mean patients may not need treatment forever

Typically patients with HIV need to stay on treatment for life but that may no longer be the case if Biotron’s (ASX:BIT) anti-HIV therapy stacks up. The biotech has found that its anti-HIV therapy can restore immune functions in HIV patient...

Stockhead BIT 1 year ago
Why the Biotron share price has soared 22% higher today

The Biotron Limited (ASX: BIT) share price is soaring higher this morning after the small-cap ASX healthcare share released more data in relation to the effectiveness of its antiviral drug, BIT225. After rocketing as much as 21.7% higher i...

Motley Fool BIT 1 year ago
Why Biotron, Karoon Energy, Pro Medicus, & WiseTech Global are pushing higher

The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is tumbling lower on Thursday. In morning trade the benchmark index is down 2.4% to 5,588.2 points. Four shares that have not let that hold them back are listed...

Motley Fool BIT 1 year ago
Gone viral: COVID-19 is making Jatenergy, AuMake so very rich

Jatenergy (ASX:JAT) shares are surging after the company said it booked record sales and revenue in February, as Chinese buyers sucked up its milk products. Revenue was $8.3m for the month. The board has lifted full year guidance from $36m...

Stockhead BIT 1 year ago
Biotron presents further Phase 2 trial results for HIV drug BIT225

Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing Phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (CROI) this week with new data showing th...

SmallCaps BIT 1 year ago
10 at 10: These ASX stocks are staying healthy in a pandemic this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead BIT 1 year ago
Your guide to COVID-19 vaccines: it’ll all be over soon

There are dozens of vaccines, antiretrovirals and new supportive therapies being feverishly tested against COVID-19, and researchers say new technologies are enabling them to move faster than ever before. COVID-19, a member of the coronavir...

Stockhead BIT 1 year ago
Dr Boreham’s Crucible: The small cap biotechs trying to make a buck from coronavirus

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

Stockhead BIT 1 year ago
These ASX shares are fighting the spread of coronavirus

The spread of coronavirus has infected global share markets with the contagion of fear. The S&P/ASX 200 Index (INDEXASX: XJO) has fallen more than 10% in the last fortnight as investors flee to safe havens. This week, the Reserve Bank...

Motley Fool BIT 1 year ago
February Winners Column: Wannabe virus fighters ride high in a rough month for stocks

In February, mounting coronavirus-led uncertainty finally culminated in a late-month share price bloodbath. After a 3 per cent gain in January, the S&P/ASX Emerging Companies Index – which gauges the health of the microcap sector – had...

Stockhead BIT 1 year ago
Health Kick Podcast: Coronavirus, HIV and hepatitis are in the sights of Aussie biotech Biotron

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Michelle Miller, chief executive of...

Stockhead BIT 1 year ago
Coronavirus outbreak shakes up ASX share market

As the coronavirus death toll rises to more than 1,000 and the World Health Organisation labels it a global health emergency, share markets are feeling the impact of the outbreak with Australian ASX-listed stocks not immune to the damage. C...

SmallCaps BIT 1 year ago